Literature DB >> 15111249

Administration of FGF-1 through transfected cells alleviates MPTP toxicity in mice.

R N McLay1, S M Freeman, J E Zadina.   

Abstract

The use of genetically modified cells to deliver growth factors has been proposed as a possible treatment for neurodegeneration, including Parkinson's disease. Here we demonstrate that the implantation of fibroblasts genetically modified to secrete fibroblast growth factor-1 (FGF) increased striatal dopamine concentrations in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mouse model of Parkinson's disease.

Entities:  

Year:  2001        PMID： 15111249     DOI： 10.1007/bf03033263

Source DB:  PubMed          Journal:  Neurotox Res        ISSN： 1029-8428            Impact factor:   3.911


  14 in total

Review 1.  Attempts to obtain neuroprotection in Parkinson's disease.

Authors:  C W Olanow
Journal:  Neurology       Date:  1997-07       Impact factor: 9.910

Review 2.  Gene therapy for Parkinson's disease.

Authors:  P Horellou; J Mallet
Journal:  Mol Neurobiol       Date:  1997-10       Impact factor: 5.590

Review 3.  Striatal dopaminoceptive system changes and motor response complications in L-dopa-treated patients with advanced Parkinson's disease.

Authors:  T N Chase; T M Engber; M M Mouradian
Journal:  Adv Neurol       Date:  1993

4.  Transplant of polymer-encapsulated cells genetically engineered to release nerve growth factor allows a normal functional development of the visual cortex in dark-reared rats.

Authors:  T Pizzorusso; V Porciatti; J L Tseng; P Aebischer; L Maffei
Journal:  Neuroscience       Date:  1997-09       Impact factor: 3.590

Review 5.  Practical aspects of the development of ex vivo and in vivo gene therapy for Parkinson's disease.

Authors:  K S Bankiewicz; S E Leff; D Nagy; S Jungles; J Rokovich; K Spratt; L Cohen; M Libonati; R O Snyder; R J Mandel
Journal:  Exp Neurol       Date:  1997-03       Impact factor: 5.330

6.  Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice.

Authors:  R E Heikkila; A Hess; R C Duvoisin
Journal:  Science       Date:  1984-06-29       Impact factor: 47.728

7.  Differential transforming abilities of non-secreted and secreted forms of human fibroblast growth factor-1.

Authors:  R Forough; Z Xi; M MacPhee; S Friedman; K A Engleka; T Sayers; R H Wiltrout; T Maciag
Journal:  J Biol Chem       Date:  1993-02-05       Impact factor: 5.157

8.  Basic FGF reverses chemical and morphological deficits in the nigrostriatal system of MPTP-treated mice.

Authors:  D Otto; K Unsicker
Journal:  J Neurosci       Date:  1990-06       Impact factor: 6.167

Review 9.  MPTP mechanisms of neurotoxicity and their implications for Parkinson's disease.

Authors:  M Gerlach; P Riederer; H Przuntek; M B Youdim
Journal:  Eur J Pharmacol       Date:  1991-12-12       Impact factor: 4.432

10.  Neurotoxic effects of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the cat. Tyrosine hydroxylase immunohistochemistry.

Authors:  J S Schneider; C H Markham
Journal:  Brain Res       Date:  1986-05-14       Impact factor: 3.252
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.